Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243716 | 1.00 | EPHX1 (0.52) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL17045258 | 0.86 | SLC6A4 (0.53) | ANPEP | |
| SCHEMBL21314254 | 0.84 | PNMT (0.49) | ANPEP | |
| SCHEMBL17045246 | 0.82 | EPHX1 (0.41) | EPHX1ANPEP | |
| SCHEMBL17045266 | 0.81 | DPP4 (0.46) | EPHX1MMP2ANPEPCYP1A2 | |
| SCHEMBL21314307 | 0.80 | PPARG (0.41) | PKM | |
| SCHEMBL21314303 | 0.80 | PPARG (0.41) | PKM | |
| SCHEMBL17045261 | 0.80 | DPP4 (0.43) | — | |
| SCHEMBL21314279 | 0.80 | ALDH1A1 (0.53) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL21314278 | 0.80 | ALDH1A1 (0.53) | EPHX1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3587394-B1 | AMINOCARBONYLCARBAMATE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HYPERKINETIC DISORDERS SUCH AS ADHD | SK BIOPHARMACEUTICALS CO LTD (KR) | 2023-11-01 | — | — | EP | claimed |
| US-20230255921-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | CELLIONBIOMED INC. (KR) | 2023-08-17 | — | — | US | claimed |
| EP-4223291-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | Cellionbiomed Inc. (KR) | 2023-08-09 | — | — | EP | claimed |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | claimed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | claimed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | claimed |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-02-13 | — | — | US | claimed |
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SK BIOPHARMACEUTICALS CO., LTD. | 2019-08-15 | — | — | US | claimed |
| US-20230255921-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | CELLIONBIOMED INC. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4223291-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | Cellionbiomed Inc. (KR) | 2023-08-09 | — | — | EP | disclosed |
| EP-3110792-B1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-20160168567-A1 | UNA SINGLE STRANDED OLIGOMERS FOR THERAPEUTICS | MARINA BIOTECH, INC. | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255921-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | KCNA3, KCNN3, KCNMA1 | EPHX1 1970/4885ALPI 4726/4885PKM 296/4885 |
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SLC6A3, SLC6A2, SLC6A4 | EPHX1 3504/4885ALPI 1778/4885PKM 3184/4885 |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | EPHX1 3504/4885ALPI 1778/4885PKM 3184/4885 |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX1 3504/4885ALPI 1778/4885PKM 3184/4885 |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX1 3504/4885ALPI 1778/4885PKM 3184/4885 |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX1 3504/4885ALPI 1778/4885PKM 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.